Education
About Us
Working with TipRanks
Follow Us
Janux Therapeutics, Inc. (JANX)
:JANX
JANX Analyst Ratings
Strong Buy
18 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
JANX Stock 12 Month Forecast
Average Price Target
$73.53
▲(219.97% Upside)
| Highest Price Target$200.00 | Average Price Target$73.53 | Lowest Price Target$25.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Barclays
$47
Buy
104.53%
Upside
Initiated
09/16/25
Bank of America Securities
$59
Buy
156.74%
Upside
Reiterated
09/11/25
Stifel Nicolaus
$45
Buy
95.82%
Upside
Initiated
09/10/25
Buy Rating for Janux Therapeutics Inc: Promising Oncology Innovations and Strategic AdvancementsWe view the development of T cell engagers (TCEs) for solid tumor applications as a thematicall and strategically relevant trend within oncology and believe JANX’s novel TRACTr platfor meaningfully expands the universe of targetable antigens via tumor-activated masking technolog – with preliminary (and unprecedented) JANX007 safety/efficacy data in heavily-pretreated mCRP (where prior iterations of PSMA-targeting TCEs have failed) encapsulating the competitive whitespac broadly existing here.
Cantor Fitzgerald
$200
Buy
770.32%
Upside
Reiterated
09/06/25
Guggenheim
$72
Buy
213.32%
Upside
Initiated
09/03/25
Piper Sandler
$42
Buy
82.77%
Upside
Reiterated
08/27/25
Leerink Partners
$89→$87
Buy
278.59%
Upside
Reiterated
08/12/25
Buy Rating for Janux Therapeutics Driven by Promising Tumor-Conditional Masking Platform and Strategic CollaborationsWe remain positive on JANX and the differential clinical potential of their tumor-conditional masking platform that promises wider therapeutic windows for potent immuno-oncology mechanisms, and for the best-in-class efficacy potential of their lead masked PSMA- targeted CD3 T-cell engager (TCE), JANX007. 2H25 risk- reward is attractive for JANX with JANX007’s planned Ph 1 update in patients with metastatic castration-resistant prostate cancer (mCRPC). We are optimistic that JANX007’s safety profile and efficacy durability can improve with further dose, schedule and adverse event (AE) management optimization, as well as with evaluation in earlier treatment lines.
H.C. Wainwright
$70
Buy
204.61%
Upside
Reiterated
08/11/25
William Blair
―
Buy
―
Reiterated
08/08/25
JonesTrading
$90
Buy
291.64%
Upside
Reiterated
08/08/25
LifeSci Capital
$100
Buy
335.16%
Upside
Reiterated
08/07/25
TD Cowen
―
Buy
―
Reiterated
08/07/25
BTIG
$100
Buy
335.16%
Upside
Reiterated
08/07/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Barclays
$47
Buy
104.53%
Upside
Initiated
09/16/25
Bank of America Securities
$59
Buy
156.74%
Upside
Reiterated
09/11/25
Stifel Nicolaus
$45
Buy
95.82%
Upside
Initiated
09/10/25
Buy Rating for Janux Therapeutics Inc: Promising Oncology Innovations and Strategic AdvancementsWe view the development of T cell engagers (TCEs) for solid tumor applications as a thematicall and strategically relevant trend within oncology and believe JANX’s novel TRACTr platfor meaningfully expands the universe of targetable antigens via tumor-activated masking technolog – with preliminary (and unprecedented) JANX007 safety/efficacy data in heavily-pretreated mCRP (where prior iterations of PSMA-targeting TCEs have failed) encapsulating the competitive whitespac broadly existing here.
Cantor Fitzgerald
$200
Buy
770.32%
Upside
Reiterated
09/06/25
Guggenheim
$72
Buy
213.32%
Upside
Initiated
09/03/25
Piper Sandler
$42
Buy
82.77%
Upside
Reiterated
08/27/25
Leerink Partners
$89→$87
Buy
278.59%
Upside
Reiterated
08/12/25
Buy Rating for Janux Therapeutics Driven by Promising Tumor-Conditional Masking Platform and Strategic CollaborationsWe remain positive on JANX and the differential clinical potential of their tumor-conditional masking platform that promises wider therapeutic windows for potent immuno-oncology mechanisms, and for the best-in-class efficacy potential of their lead masked PSMA- targeted CD3 T-cell engager (TCE), JANX007. 2H25 risk- reward is attractive for JANX with JANX007’s planned Ph 1 update in patients with metastatic castration-resistant prostate cancer (mCRPC). We are optimistic that JANX007’s safety profile and efficacy durability can improve with further dose, schedule and adverse event (AE) management optimization, as well as with evaluation in earlier treatment lines.
H.C. Wainwright
$70
Buy
204.61%
Upside
Reiterated
08/11/25
William Blair
―
Buy
―
Reiterated
08/08/25
JonesTrading
$90
Buy
291.64%
Upside
Reiterated
08/08/25
LifeSci Capital
$100
Buy
335.16%
Upside
Reiterated
08/07/25
TD Cowen
―
Buy
―
Reiterated
08/07/25
BTIG
$100
Buy
335.16%
Upside
Reiterated
08/07/25
Best Analysts Covering Janux Therapeutics Inc
1 Month
xxx
Success Rate
6/12 ratings generated profit
Average Return
+4.39%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +4.39% per trade.
3 Months
xxx
Success Rate
4/10 ratings generated profit
Average Return
-3.88%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -3.88% per trade.
1 Year
Success Rate
6/15 ratings generated profit
Average Return
+79.47%
reiterated a buy rating 2 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +79.47% per trade.
2 Years
xxx
Success Rate
6/15 ratings generated profit
Average Return
+18.96%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of +18.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
JANX Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
13
12
19
17
23
Buy
5
5
10
8
7
Hold
4
5
8
9
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
22
37
34
42
Each month's total comprises the sum of three months' worth of ratings.
JANX Financial Forecast
JANX Stock Forecast FAQ
What is JANX’s average 12-month price target, according to analysts?
Based on analyst ratings, Janux Therapeutics, Inc.’s 12-month average price target is 73.53.
What is JANX’s upside potential, based on the analysts’ average price target?
Janux Therapeutics, Inc. has 219.97% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is JANX a Buy, Sell or Hold?
Janux Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 18 buy ratings, 1 hold ratings and 0 sell ratings.
What is Janux Therapeutics, Inc.’s price target?
The average price target for Janux Therapeutics, Inc. is 73.53. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $200.00 ,the lowest forecast is $25.00. The average price target represents 219.97% Increase from the current price of $22.98.
The highest analyst price target is $200.00 ,the lowest forecast is $25.00. The average price target represents 219.97% Increase from the current price of $22.98.
What do analysts say about Janux Therapeutics, Inc.?
Janux Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
How can I buy shares of JANX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.